BISPECIFIC T-CELL ENGAGER
Epkinly is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, in adults who have already tried two types of systemic therapy. Epkinly may be referred to by its drug name, epcoritamab-bysp.
Epkinly is a bispecific T-cell engager. The drug consists of a genetically engineered protein, or antibody, that targets the CD20 protein on lymphoma B cells and the CD3 protein on T cells. Epkinly is believed to work by inducing T cells to kill lymphoma B cells.
How do I take it?
Epkinly is administered as a subcutaneous (under the skin) injection on specific days in cycles of 28 days. Epkinly comes in the form of a single-dose vial.
The FDA-approved label for Epkinly lists common side effects including cytokine release syndrome (CRS), a potentially fatal inflammatory reaction with severe neurological symptoms such as hallucinations and tremors. Other common side effects are fatigue, muscle pain, bone and joint pain, injection site reactions, fever, abdominal pain, nausea, and diarrhea.
Other rare but serious side effects listed for Epkinly can include infections, abnormal blood counts, and fetal harm.
For more details about this treatment, visit:
Epkinly — Genmab and AbbVie